Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy
Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2022-11-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3422 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849698877683269632 |
|---|---|
| author | V. P. Mikhin O. A. Osipova V. V. Vorotyntseva D. N. Perutsky N. I. Golovina |
| author_facet | V. P. Mikhin O. A. Osipova V. V. Vorotyntseva D. N. Perutsky N. I. Golovina |
| author_sort | V. P. Mikhin |
| collection | DOAJ |
| description | Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p<0,05), while there were no differences in MMP-1 when using low and medium doses. Rosuvastatin had a less pronounced effect on MMP-9 than on MMP-1, while increasing the dose of rosuvastatin did not affect the intensity of MMP-9 reduction (p>0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood. |
| format | Article |
| id | doaj-art-eb251dfcfc13451c8c6731336ad50df4 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-eb251dfcfc13451c8c6731336ad50df42025-08-20T03:18:46Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252022-11-01211010.15829/1728-8800-2022-34222568Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapyV. P. Mikhin0O. A. Osipova1V. V. Vorotyntseva2D. N. Perutsky3N. I. Golovina4Kursk State Medical UniversityBelgorod State National Research UniversityKursk City Clinical Emergency HospitalBelgorod State National Research UniversityBelgorod State National Research UniversityAim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p<0,05), while there were no differences in MMP-1 when using low and medium doses. Rosuvastatin had a less pronounced effect on MMP-9 than on MMP-1, while increasing the dose of rosuvastatin did not affect the intensity of MMP-9 reduction (p>0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood.https://cardiovascular.elpub.ru/jour/article/view/3422hypertensioncardiovascular riskstatinsmatrix metalloproteinasestissue inhibitors of metalloproteinases |
| spellingShingle | V. P. Mikhin O. A. Osipova V. V. Vorotyntseva D. N. Perutsky N. I. Golovina Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy Кардиоваскулярная терапия и профилактика hypertension cardiovascular risk statins matrix metalloproteinases tissue inhibitors of metalloproteinases |
| title | Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| title_full | Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| title_fullStr | Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| title_full_unstemmed | Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| title_short | Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| title_sort | content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy |
| topic | hypertension cardiovascular risk statins matrix metalloproteinases tissue inhibitors of metalloproteinases |
| url | https://cardiovascular.elpub.ru/jour/article/view/3422 |
| work_keys_str_mv | AT vpmikhin contentofmatrixmetalloproteinasesinthebloodofhypertensivepatientswithahighcardiovascularriskreceivingstatintherapy AT oaosipova contentofmatrixmetalloproteinasesinthebloodofhypertensivepatientswithahighcardiovascularriskreceivingstatintherapy AT vvvorotyntseva contentofmatrixmetalloproteinasesinthebloodofhypertensivepatientswithahighcardiovascularriskreceivingstatintherapy AT dnperutsky contentofmatrixmetalloproteinasesinthebloodofhypertensivepatientswithahighcardiovascularriskreceivingstatintherapy AT nigolovina contentofmatrixmetalloproteinasesinthebloodofhypertensivepatientswithahighcardiovascularriskreceivingstatintherapy |